Uncategorized

IRLAB to Present Data from the Phase IIb Study of Mesdopetam in PD-LIDs at the MDS Congress 2023

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company will present an abstract at the International Congress of Parkinson’s Disease and Movement Disorders®, MDS Congress, in Copenhagen, Denmark from August 27-31, 2023.

IRLAB to Present Data from the Phase IIb Study of Mesdopetam in PD-LIDs at the MDS Congress 2023 Read More »

Santhera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royalties

Santhera Pharmaceuticals announces that it has signed an exclusive license and collaboration agreement for vamorolone in North America with Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on novel medicines for patients living with rare diseases.

Santhera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royalties Read More »

Scroll to Top